NATDAC

NatDac

Read more

Daclatasvir is the first-in-class NS5A inhibitor used in combination with Sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection.

Product Description

Daclatasvir is the first-in-class NS5A inhibitor used in combination with Sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection.

Reviews

There are no reviews yet.

Be the first to review “NatDac”

Your email address will not be published. Required fields are marked *